Product Information
ETRAVIRINE 200 MG TABLET is a generic product labeled by Leading Pharma, LLC, priced at $9.9434 per EA under NDC 69315028606. Its NADAC has been published 217 times since Aug 10, 2022.
FDA first approved this application on Apr 13, 2022. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
Strength
200 mg/1
Manufacturer
Leading Pharma, LLCNDC
69315028606
Classification
Generic
Dosage Form
TABLET
Route
ORAL
Effective Date
9/23/2026
Active Ingredients
ETRAVIRINEApproval Type
Generic (ANDA)
FDA Application
ANDA215402FDA Approved
4/13/2022
TE Code
AB
On Market Since
6/5/2022
Pharmacological Classes
Price Statistics
The NADAC for ETRAVIRINE 200 MG TABLET has been published 217 times since Aug 10, 2022, and over the history we have for it it has declined 43.9%. The table below summarizes its recorded NADAC range and movement.
| Current price | $9.9434 per EA |
|---|---|
| All-time high | $17.7091 (Mar 15, 2023) |
| All-time low | $9.9434 (Sep 23, 2026) |
| 52-week high | $11.7118 |
| 52-week low | $9.9434 |
| Median price | $13.1617 |
| Average price | $13.9313 |
| Largest weekly change | +13.4% (Oct 23, 2024) |
| Weeks tracked | 217 |
| Tracking since | Aug 10, 2022 |
Generic Alternatives
No other NADAC-published product shares this drug's active ingredient and strength in a comparable dosage form. Compare the broader picture on the ETRAVIRINE market page.
Lowest-Cost Alternatives
No alternatives available
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Leading Pharma, LLC manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
ETRAVIRINE market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Human Immunodeficiency Virus 1 Non-Nucleoside Analog Reverse Transcriptase Inhibitor class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of ETRAVIRINE 200 MG TABLET?
The current National Average Drug Acquisition Cost (NADAC) for ETRAVIRINE 200 MG TABLET, manufactured by Leading Pharma, LLC, is $9.9434 per EA (NDC 69315028606), effective Sep 30, 2026.
How has the price of ETRAVIRINE 200 MG TABLET changed over time?
Over the history we have for it, the NADAC for ETRAVIRINE 200 MG TABLET has declined 43.9%. It has been tracked across 217 weekly CMS publications since Aug 10, 2022.
What are the highest and lowest recorded NADAC prices for ETRAVIRINE 200 MG TABLET?
Since Aug 10, 2022, the NADAC for ETRAVIRINE 200 MG TABLET has ranged from a low of $9.9434 (Sep 23, 2026) to a high of $17.7091 (Mar 15, 2023), with a median of $13.1617 per EA.
Are there cheaper alternatives to ETRAVIRINE 200 MG TABLET?
No other NADAC-published product currently shares the active ingredient and strength of ETRAVIRINE 200 MG TABLET in a comparable dosage form, so no direct lower-cost alternative is listed.
Who manufactures ETRAVIRINE 200 MG TABLET?
ETRAVIRINE 200 MG TABLET (NDC 69315028606) is labeled by Leading Pharma, LLC, and CMS classifies it as a generic product.